726174-52-3

Usage

Uses

Used in Pharmaceutical and Drug Development:
(6-Hydroxy-benzofuran-3-yl)-acetic acid methyl ester is used as a pharmaceutical compound for its potential biological activities, including antioxidant, anticancer, and anti-inflammatory properties. Its diverse pharmacological activities make it a promising candidate for the development of new drugs and therapies.
Used in Chemical Analysis and Research:
(6-Hydroxy-benzofuran-3-yl)-acetic acid methyl ester is used as a reference standard in chemical analysis and research. Its unique properties and structure make it valuable for studying and comparing with other compounds in various scientific investigations.
Used in Antioxidant Applications:
(6-Hydroxy-benzofuran-3-yl)-acetic acid methyl ester is used as an antioxidant agent for its potential to protect cells and tissues from oxidative damage. Its antioxidant properties can be beneficial in preventing various diseases and conditions associated with oxidative stress.
Used in Anti-inflammatory Applications:
(6-Hydroxy-benzofuran-3-yl)-acetic acid methyl ester is used as an anti-inflammatory agent for its potential to reduce inflammation and alleviate symptoms associated with inflammatory conditions. Its anti-inflammatory properties can be useful in the treatment of various diseases and disorders characterized by inflammation.
Used in Anticancer Applications:
(6-Hydroxy-benzofuran-3-yl)-acetic acid methyl ester is used as an anticancer agent for its potential to inhibit the growth and proliferation of cancer cells. Its anticancer properties can be employed in the development of new therapeutic strategies for the treatment of various types of cancer.
Used in Different Industries:
(6-Hydroxy-benzofuran-3-yl)-acetic acid methyl ester can be used in various industries, such as pharmaceuticals, cosmetics, and food and beverage, due to its diverse applications and potential benefits. Its use in these industries can contribute to the development of innovative products and solutions that leverage its unique properties and capabilities.

Upstream product

• 6272-26-0 6-hydroxybenzofuran-3-one 
• 21204-67-1 methyl (triphenylphosphoranylidene)acetate 

Downstream Products

• 945774-05-0 C₂₆H₂₁F₃O₅ 
• 69716-05-8 2-(6-methoxy-1-benzofuran-3-yl)acetic acid 
• 1609194-88-8 C₁₁H₁₂O₄ 
• 1613300-92-7 [(S)-6-{(R)-7-fluoro-4-[4-(1-methyl-1H-tetrazol-5-yl)phenoxy]indan-1-yloxy}-2,3-dihydrobenzofuran-3-yl]acetic acid methyl ester 
• 1613300-93-8 [(S)-6-{(R)-7-fluoro-4-[4-(2-methyl-2H-tetrazol-5-yl)phenoxy]indan-1-yloxy}-2,3-dihydrobenzofuran-3-yl]acetic acid methyl ester 
• 1613300-79-0 [(S)-6-{(R)-7-fluoro-4-[4-(2-methoxyethoxy)phenoxy]indan-1-yloxy}-2,3-dihydrobenzofuran-3-yl]acetic acid methyl ester 
• 1613300-78-9 {(S)-6-[(R)-7-fluoro-4-(4-hydroxyphenoxy)indan-1-yloxy]-2,3-dihydrobenzofuran-3-yl}acetic acid methyl ester 
• 1613300-07-4 [(S)-6-{(R)-7-fluoro-4-[4-(2-methoxyethoxy)phenoxy]indan-1-yloxy}-2,3-dihydrobenzofuran-3-yl]acetic acid 
• 1613300-77-8 [(S)-6-{(R)-4-[4-(benzyloxy)phenoxy]-7-fluoroindan-1-yloxy}-2,3-dihydrobenzofuran-3-yl]acetic acid methyl ester 

Relevant academic research and scientific papers

BICYCLIC DERIVATIVES AS PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) R2 is selected from the group consisting of C0-C8 alkyl and C1-4- heteroalkyl; (b) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (c) U is an aliphatic linker wherein one carbon atom of the aliphatic linker is optionally replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with from one to four substituents each independently selected from R30; (d) Y is selected from the group consisting of C, O, S, NH and a single bond; and (e) E is C(R3)(R4)A or A.

FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S. S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.